Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Transl Med ; 15(717): eade1844, 2023 10 11.
Article in English | MEDLINE | ID: mdl-37820007

ABSTRACT

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Although cSCC contributes to substantial morbidity and mortality in high-risk individuals, deployment of otherwise effective chemoprevention of cSCC is limited by toxicities. Our systematic computational drug repurposing screen predicted that selumetinib, a MAPK (mitogen-activated protein kinase) kinase inhibitor (MEKi), would reverse transcriptional signatures associated with cSCC development, consistent with our genomic analysis implicating MEK as a chemoprevention target. Although systemic MEKi suppresses the formation of cSCC in mice, systemic MEKi can cause severe adverse effects. Here, we report the development of a metabolically labile MEKi, NFX-179, designed to potently and selectively suppress the MAPK pathway in the skin before rapid metabolism in the systemic circulation. NFX-179 was identified on the basis of its biochemical and cellular potency, selectivity, and rapid metabolism upon systemic absorption. In our ultraviolet-induced cSCC mouse model, topical application of NFX-179 gel reduced the formation of new cSCCs by an average of 60% at doses of 0.1% and greater at 28 days. We further confirmed the localized nature of these effects in an additional split-mouse randomized controlled study where suppression of cSCC was observed only in drug-treated areas. No toxicities were observed. NFX-179 inhibits the growth of human SCC cell lines in a dose-dependent manner, and topical NFX-179 application penetrates human skin and inhibits MAPK signaling in human cSCC explants. Together, our data provide a compelling rationale for using topical MEK inhibition through the application of NFX-179 gel as an effective strategy for cSCC chemoprevention.


Subject(s)
Carcinoma, Squamous Cell , Skin Neoplasms , Animals , Humans , Mice , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/genetics , Cell Proliferation , Chemoprevention , Mitogen-Activated Protein Kinase Kinases , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/therapeutic use , Skin Neoplasms/drug therapy , Skin Neoplasms/prevention & control , Skin Neoplasms/genetics
2.
J Pharm Sci ; 104(3): 803-12, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25830179

ABSTRACT

This paper assesses the current regulatory environment, relevant regulations and guidelines, and their impact on continuous manufacturing. It summarizes current regulatory experience and learning from both review and inspection perspectives. It outlines key regulatory aspects, including continuous manufacturing process description and control strategy in regulatory files, process validation, and key Good Manufacturing Practice (GMP) requirements. In addition, the paper identifies regulatory gaps and challenges and proposes a way forward to facilitate implementation.


Subject(s)
Drug Industry/legislation & jurisprudence , Legislation, Drug , Pharmaceutical Preparations/chemical synthesis , Quality Control , Technology, Pharmaceutical/legislation & jurisprudence , Workflow , Consumer Product Safety , Drug Contamination/legislation & jurisprudence , Drug Contamination/prevention & control , Drug Industry/instrumentation , Drug Industry/methods , Drug Industry/standards , Drug Industry/trends , Equipment Contamination/legislation & jurisprudence , Equipment Contamination/prevention & control , Equipment Failure , Europe , Guidelines as Topic , Humans , Legislation, Drug/trends , Patient Safety , Pharmaceutical Preparations/standards , Technology, Pharmaceutical/instrumentation , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/standards , Technology, Pharmaceutical/trends , United States , United States Food and Drug Administration
3.
J Pharm Sci ; 104(3): 803-812, 2015 Mar.
Article in English | MEDLINE | ID: mdl-28756842

ABSTRACT

This paper assesses the current regulatory environment, relevant regulations and guidelines, and their impact on continuous manufacturing. It summarizes current regulatory experience and learning from both review and inspection perspectives. It outlines key regulatory aspects, including continuous manufacturing process description and control strategy in regulatory files, process validation, and key Good Manufacturing Practice (GMP) requirements. In addition, the paper identifies regulatory gaps and challenges and proposes a way forward to facilitate implementation. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.

4.
AAPS J ; 17(1): 44-64, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25421459

ABSTRACT

At the Product Quality Research Institute (PQRI) Workshop held last January 14-15, 2014, participants from academia, industry, and governmental agencies involved in the development and regulation of nanomedicines discussed the current state of characterization, formulation development, manufacturing, and nonclinical safety evaluation of nanomaterial-containing drug products for human use. The workshop discussions identified areas where additional understanding of material attributes, absorption, biodistribution, cellular and tissue uptake, and disposition of nanosized particles would continue to inform their safe use in drug products. Analytical techniques and methods used for in vitro characterization and stability testing of formulations containing nanomaterials were discussed, along with their advantages and limitations. Areas where additional regulatory guidance and material characterization standards would help in the development and approval of nanomedicines were explored. Representatives from the US Food and Drug Administration (USFDA), Health Canada, and European Medicines Agency (EMA) presented information about the diversity of nanomaterials in approved and newly developed drug products. USFDA, Health Canada, and EMA regulators discussed the applicability of current regulatory policies in presentations and open discussion. Information contained in several of the recent EMA reflection papers was discussed in detail, along with their scope and intent to enhance scientific understanding about disposition, efficacy, and safety of nanomaterials introduced in vivo and regulatory requirements for testing and market authorization. Opportunities for interaction with regulatory agencies during the lifecycle of nanomedicines were also addressed at the meeting. This is a summary of the workshop presentations and discussions, including considerations for future regulatory guidance on drug products containing nanomaterials.


Subject(s)
Drug Design , Nanostructures , Pharmaceutical Preparations/administration & dosage , Animals , Chemistry, Pharmaceutical , Drug Approval , Drug and Narcotic Control , Humans , Nanoparticles , Pharmaceutical Preparations/chemistry , Tissue Distribution
5.
AAPS J ; 15(3): 623-8, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23512727

ABSTRACT

The Nanotechnology Risk Assessment Working Group in the Center for Drug Evaluation and Research (CDER) within the United States Food and Drug Administration was established to assess the possible impact of nanotechnology on drug products. The group is in the process of performing risk assessment and management exercises. The task of the working group is to identify areas where CDER may need to optimize its review practices and to develop standards to ensure review consistency for drug applications that may involve the application of nanotechnology. The working group already performed risk management exercises evaluating the potential risks from administering nanomaterial active pharmaceutical ingredients (API) or nanomaterial excipients by various routes of administration. This publication outlines the risk assessment and management process used by the working group, using nanomaterial API by the oral route of administration as an example.


Subject(s)
Drug Approval/methods , Nanostructures/standards , Pharmaceutical Preparations/standards , Drug Evaluation/methods , Drug Evaluation/standards , Humans , Nanostructures/adverse effects , Risk Assessment/methods , Risk Assessment/standards , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...